Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) will announce its fourth quarter and full year 2021 financial results on February 24, 2022, after U.S. markets close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide updates. Kura is focused on precision medicines for cancer treatment, with key developments including KO-539 in clinical trials for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma, which has received Breakthrough Therapy Designation.

Positive

• Tipifarnib has received Breakthrough Therapy Designation for HRAS mutant head and neck squamous cell carcinoma.
• Ongoing clinical trials for KO-539 and tipifarnib indicate progress in innovative cancer treatments.

Negative

• None.

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 8645626. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also developing KO-2806, a next-generation FTI, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When will Kura Oncology report its financial results?

Kura Oncology will report its fourth quarter and full year 2021 financial results on February 24, 2022.

What time is Kura Oncology's conference call?

The conference call is scheduled for 4:30 p.m. ET on February 24, 2022.

What is the significance of Breakthrough Therapy Designation for Kura Oncology?

Breakthrough Therapy Designation for tipifarnib accelerates its development for patients with HRAS mutant head and neck squamous cell carcinoma.

What are the main focuses of Kura Oncology's clinical trials?

Kura Oncology's clinical trials are focused on innovative cancer treatments, including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma.